Susquehanna International Group, LLP Delcath Systems, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 14, 2025	SELL	$11.43 - $16.45 $849,249 - $1.22 Million	-74,300 Reduced 82.65%	15,600 $198,000
Q4 2024 Feb 14, 2025	SELL	$8.32 - $12.64 $385,216 - $585,232	-46,300 Reduced 33.99%	89,900 $1.06 Million
Q3 2024 Nov 14, 2024	BUY	$7.36 - $11.0 $256,864 - $383,900	34,900 Added 34.45%	136,200 $1.23 Million
Q2 2024 Aug 15, 2024	SELL	$4.47 - $8.37 $143,040 - $267,840	-32,000 Reduced 24.01%	101,300 $847,000
Q1 2024 May 07, 2024	BUY	$3.72 - $5.09 $376,464 - $515,108	101,200 Added 315.26%	133,300 $635,000
Q4 2023 Feb 14, 2024	SELL	$2.25 - $4.17 $131,625 - $243,945	-58,500 Reduced 64.57%	32,100 $133,000
Q3 2023 Nov 14, 2023	BUY	$3.12 - $5.85 $282,672 - $530,010	90,600 New	90,600 $366,000

104

12.1M

79K

53.3K

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $126M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.